Summary Mucinous carcinomas are defined on the basis of the amount of the mucus component in the tumour mass. Apart from this quantitative criterion, a number of clinicopathological parameters (such as localisation, prevalence in different countries and age groups, association with HNPCC and inflammatory processes) and genetic alterations (e.g. frequency of mutation in Ki-ras and p53 genes, level of MUC2 expression) differentiate these tumours from the non-mucinous ones. Since a different set of genetic lesions implies different inducing agents, these observations suggest that there may be a 'mucinous pathway of carcinogenesis'. Further identification of genetic changes characteristic of the mucinous phenotype will help to understand the aetiology of these tumours and possibly establish markers for detection of the high-risk group.
The designation mucinous carcinomas is applied to colorectal tumours in which mucus secretion largely contributes to the tumour growth. Different authors classified colonic tumours as mucinous when the mucin lakes represented 50% (Pihl et al., 1980) to 80% (Umpleby et al., 1985) of the tissue; the definition set by World Health Organization and applied in the more recent reports and in the present minireview requires the mucinous component to represent more than 50% of the tumour (Jass and Sobin, 1990) .
Whether the mucinous phenotype is associated with relatively poor prognosis is a matter of controversy; more recent multivariate analyses of the course of the disease in a large number of patients indicate that the mucinous carcinomas of the colorectum do not differ in their clinical behaviour from non-mucinous (Sasaki et al., 1987; Halvorsen and Seim, 1988; Hermanek et al., 1989) or signet ring cell carcinomas (Sasaki et al., 1987) . The pattern of the genetic lesions in mucinous carcinomas is, however, different from that in non-mucinous ones. Some of these differences are obviously related to the mucinous phenotype (like the level of MUC2 expression) and may be epiphenomenal, while others (such as activation of proto-oncogenes and inactivation of suppressor genes) belong to the group of lesions assumed to be fundamental in carcinogenesis. The present analysis of the recently defined genetic differences as well as indicators of inherent genetic differences between the mucinous and nonmucinous phenotype suggests that distinct molecular lesions occur during the development of these two types of colorectal carcinoma.
Clinicopathological parameters
Similar prevalence in the left and the right colon Several studies indicate that 19-40% of non-mucinous sporadic carcinomas are located in the right colon while the majority is found in the left colon (Symonds and Vickery, 1976; Umpleby et al., 1985; Milne, 1994) . By contrast, the prevalence of mucinous carcinomas is approximately equal in both segments (Symonds and Vickery, 1976; Sundblad and Paz, 1982; Umpleby et al., 1985) . For example, in a recent study of 80 mucinous carcinomas 46% were localised in the right (including ascending and transverse colon) and 54% in the left colon segment (including descending, sigmoid colon and rectum). Among patients with non-mucinous carcinomas this distribution was 19% and 81% respectively (Hanski et al., 1995) . Thus in the right colon about every fifth, while in the left colon every tenth, tumour exhibits a mucinous phenotype.
This difference in preferential localisation suggests that the development of mucinous tumours, in contrast to nonmucinous ones, is less dependent on endogenous factors that show a proximal-to-distal gradient.
Different prevalence in different countries
There are no separate data on the incidence of colorectal mucinous carcinomas in different countries. They can, however, be estimated from the available prevalence of mucinous carcinomas and the incidence of sporadic colon carcinomas. Since the available data do not take into account potential variations in the prevalence of inherited cancer syndromes, they can be compared only if the assumption is made that inherited cancers represented a minor fraction of the investigated tumours.
For example, the prevalence of mucinous carcinomas among all sporadic colorectal carcinomas ranges from 6% in Japan (Okuno et al., 1988; Yamamoto et al., 1993) to 15% in the USA (Symonds and Vickery, 1976) . Since large patient groups have been evaluated according to similar criteria, these variations are unlikely to be due to a sampling error. While the incidence of sporadic colon carcinomas is less than 3-fold higher in the USA than in Japan, the resulting annual incidence of mucinous cancers is about 7-fold higher in the USA. Thus the incidence pattern of mucinous carcinomas appears to show a different dependence from the life and dietary conditions than that of non-mucinous adenocarcinomas of the colon.
Different prevalence in young and elderly age groups
The non-mucinous carcinoma is most frequent in 60-69-year-old patients (Umpleby et al., 1985; Hanski et al., 1995) while the mucinous carcinoma is most frequent at the age 70-79 years. In patients younger than 20 years colon carcinoma is extremely rare (incidence 1 in 10 million) but . Mucinous (1994) Peltomaki, 1994; Loeb, 1994; Peltomaki, 1994; Smith, 1994 (Hamilton, 1985) or 29% (Choi and Zelig, 1994) Incidence of all cancers is an estimate derived from the IARC statistics on cancer incidence in different countries (Waterhouse et al., 1982) . The incidence of mucinous carcinomas is calculated from the prevalence data in individual reports. The percentage of mucin in the sections used by each author to define the mucinous phenotype is given in brackets. aIn tumours defined as mucinous the mucinous component was predominant.
malignancies not associated with virus and in sarcomas without MDM2 amplification (Chang et al., 1993) .
The mechanism underlying the formation of mucinous carcinoma in the presence of intact p53 is not known. The data obtained on human colorectal carcinomas are supported by observations made in vitro. Progression of the adenomaderived cell line PC/AA to the mucinous malignant phenotype did not involve p53 protein overexpression, while progression to the adenocarcinoma phenotype was associated with the increase of cellular p53 protein expression (Williams et al., 1993) . Similarly, a spontaneous progression of a colonic adenoma cell line VACO-235 to mucinous carcinoma occurred without mutations in the p53 gene (Markowitz et al., 1994) .
It is of particular interest that, similarly to colorectal tumours, the mucinous carcinomas of the pancreas (Hoshi et al., 1994; Zhang et al., 1994) , breast (Domagala et al., 1993; Marchetti et al., 1993) and ovary (Milner et al., 1993; Rennison et al., 1994) show either no alterations in the p53 gene nor in its expression, or the alterations are significantly less frequent than in the non-mucinous tumours of the same organs.
While the p53 gene, which is located on chromosome 17p, appears to be less frequently mutated in mucinous tumours, the less frequent loss of heterozygosity in mucinous than in non-mucinous tumours was observed not only on chromosome 17p (44% vs 88%) but also on chromosome 18q (47% vs 85%) (Kern et al., 1989) . Since the loss of heterozygosity on chromosome 17p or 18q, however, is generally less frequent in proximal than in the distal colon (Thibodeau et al., 1993) , the correlation of this property with the mucinous phenotype must be verified on selected tumours of either type from the proximal colon.
In tumours with non-mutated p53 the DNA index (which is the ratio of DNA content of malignant cells to that of normal cells) was reported to be lower than in those with mutated p53 (Hamelin et al., 1994a) , which would imply that mucinous tumours may have a lower DNA index than nonmucinous ones. Indeed, in mucinous tumours a higher incidence of diploid pattern (Kanagawa et al., 1992 ) and a lower DNA index than in the non-mucinous tumours (Lanza et al., 1994) were observed, the latter apparently being independent from tumour location (Lanza et al., 1994) .
High frequency of mutations in Ki-ras proto-oncogene Ki-ras protein p21 belongs to the family of GTP/GDP binding proteins with GTPase activity, which participate in transduction of mitogenic signals from the membrane to the cell nucleus (Lowy and Willumsen, 1993) . Mutated ras proteins have a reduced GTPase activity and/or an increased dissociation rate of ras-GDP, leading to a prolonged mitogenic signal (Egan and Weinberg, 1993) .
Single-point mutations in the Ki-ras proto-oncogene leading to substitution of critical amino acid residues in the p21 protein are sufficient to confer transforming properties to this gene (Reddy et al., 1982) . In human colorectal carcinogenesis the alterations of the Ki-ras gene appear to occur during the early steps of tumour formation, particularly during the development of adenomatous polyps (Farr et al., 1988; Vogelstein et al., 1988) . The prevalence of Ki-ras mutations increases in adenomas at a more advanced stage of progression (Forrester et al., 1987; Fearon and Vogelstein, 1990) and reaches 50% in non-selected carcinomas (Fearon and Vogelstein, 1990) . In mucinous adenocarcinomas the codons 12 and 13 are affected in 65% of cases, while in non-mucinous ones the mutations occur in only 33% of these loci (Laurent Puig et al., 1991) . Of interest, in mucinous ovarian tumours the prevalence of Ki-ras mutations is higher than in the non-mucinous ones (Enomoto et al., 1991; Ichikawa et al., 1994) , indicating that also in ovarian tumours the high frequency of Ki-ras mutation is preferentially associated with the mucinous phenotype.
Amplification of c-myc proto-oncogene
The c-myc-coded dimeric nuclear phosphoprotein binds to DNA and regulates gene transcription; therefore it has potential importance as a determinant of the proliferation state of the cell (Kretzner et al., 1985; Dang, 1991; Marcu et al., 1992 , 1992) . The activation of the c-myc gene may be of relevance for progression of colonic tumours since the increase in -expression of c-myc mRNA and its protein product correlates with dysplasia grade in adenomas and with the progression from adenoma to colon carcinoma Rothberg et al., 1985; Sikora et al., 1987; Finley et al., 1989; Agnantis et al., 1991; Pavelic et al., 1992; Tulchin et al., 1992; Hanski et al., 1994; Sato et al., 1994) . The c-myc proto-oncogene is present as a single copy gene in the normal human genome. In 54% of mucinous colorectal carcinomas in a group of 13 American patients a modest amplification of the c-myc gene was found, as compared with 7% (2/29) in moderately to well-differentiated non-mucinous carcinomas (Heerdt et al., 1991) . These authors associated c-myc amplification with the more aggressive, malignant phenotype (Heerdt et al., 1991) , a finding corroborated by other workers (Kozma et al., 1994) . In a study of 100 Asian patients with colorectal cancer, however, no c-myc gene amplification was detected (Smith et al., 1993) . Further, the tumours located distal to the transverse colon (the majority of which are non-mucinous) overexpress c-myc more frequently than the proximal tumours (Rothberg, 1987) . The slight increase in gene copy number detected in the American patients (Heerdt et al., 1991) may have little effect on the c-myc message expression, however, it indicates a different frequency of proto-oncogene lesion in mucinous and nonmucinous tumours in this group of patients.
Frequent overexpression of mucin MUC2 MUC2 is a well-characterised intestinal mucin, present predominantly in the small intestine and in the colon (Ho et al., 1993) . Strong expression is observed in 72% of the mucinous but only in 21 % of non-mucinous colonic carcinomas. Also 40-48% of colonic adenomas show strong MUC2 expression. The comparison of expression in the premalignant and malignant colonic tissues of the same specimens indicated that MUC2 overexpression occurring in the adenoma tissue is maintained or increased if the adenoma progresses to mucinous carcinoma. If, however, the adenoma develops into a non-mucinous adenocarcinoma, the expression frequently decreases below the normal level (Blank et al., 1994) . Thus the overexpression of MUC2 is occurring already in the premalignant stage of the adenoma-carcinoma sequence and remains a characteristic property of the mucinous phenotype of colorectal tumours (Ho et al., 1993; Blank et al., 1994) .
The mechanisms responsible for MUC2 overexpression in mucinous carcinomas is not known. The overexpression of MUC2 in colon adenocarcinoma cells in vitro can be induced by 12-O-tetradecanoyl phorbol acetate (TPA) or forskolin. Both inducers have been shown to operate by triggering their respective signal transduction pathways, via protein kinase C-(TPA) or protein kinase A-(forskolin) (Velcich and Augenlicht, 1993) . Whether these transduction pathways are involved in the MUC2 overexpression in vivo, has not been investigated.
More frequent loss or low expression of major histocompatibility complex (MHC) class I molecules
The products of the MHC play an important role in the regulation of several immune functions: MHC class I molecules serve as restriction elements for T-cell-mediated cytotoxicity, whereas MHC class II molecules are required for the presentation of antigens to autologous helper T cells, MHC class I molecules are strongly expressed on morphologically normal colonic epithelial cells and in colonic adenomas (Van den Ingh et al., 1987; Garrido et al., 1993) . The investigation of 152 patients indicated that about 44% of non-selected carcinomas exhibit a reduction or loss of MHC class I molecules (Moller et al., 1991) . The same study indicated that the low expression or loss of MHC class I antigens is more frequent in mucinous than in non-mucinous tumours, a finding corroborating previous data from a smaller group of patients (Van den Ingh et al., 1987) .
The mechanism of MHC class I loss in carcinomas is not known. Only two cumulative mutations in P2-microglobulin (02-M) genes would be sufficient to induce complete loss of MHC class I antigens. MHC class I-negative colon carcinomas lack also P2-M expression which was interpreted as an indication that this may be the mechanism of MHC class I loss in these tumours (Momburg and Koch, 1989; Cabrera et al., 1991 (Bronner et al., 1994; Loeb, 1994; Papadopoulos et al., 1994; Peltomaki, 1994; Eshleman and Markowitz, 1995 the genetic lesions of mucinous and non-mucinous tumours would further our understanding of factors affecting differentiation in colorectal cancer. Identification of the genetic changes characteristic of the mucinous phenotype may help not only to better understand its aetiology but possibly establish markers for detection and surveillance of the high-risk population.
